Evrofarma Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Evrofarma.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Food winstgroei	9.6%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Oct 02

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Feb 29

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Jan 06

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Evrofarma onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

ATSE:EVROF - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	47	2	2	5	N/A
3/31/2024	48	2	1	4	N/A
12/31/2023	49	2	1	3	N/A
9/30/2023	49	3	1	3	N/A
6/30/2023	49	3	1	3	N/A
3/31/2023	47	2	1	3	N/A
12/31/2022	45	1	1	3	N/A
9/30/2022	42	0	-1	1	N/A
6/30/2022	39	-1	-3	0	N/A
3/31/2022	38	-1	-4	0	N/A
12/31/2021	37	0	-4	-1	N/A
9/30/2021	36	1	-3	-1	N/A
6/30/2021	36	1	-2	-1	N/A
3/31/2021	35	1	-1	0	N/A
12/31/2020	34	1	1	1	N/A
9/30/2020	33	1	1	2	N/A
6/30/2020	32	0	2	2	N/A
3/31/2020	33	0	1	2	N/A
12/31/2019	33	0	1	2	N/A
9/30/2019	34	0	0	1	N/A
6/30/2019	35	1	0	1	N/A
3/31/2019	34	1	1	2	N/A
12/31/2018	33	1	1	2	N/A
9/30/2018	32	1	2	3	N/A
6/30/2018	31	1	2	3	N/A
3/31/2018	31	1	N/A	3	N/A
12/31/2017	31	1	N/A	3	N/A
9/30/2017	31	0	N/A	3	N/A
6/30/2017	30	0	N/A	3	N/A
3/31/2017	30	0	N/A	2	N/A
12/31/2016	29	0	N/A	1	N/A
9/30/2016	28	0	N/A	0	N/A
6/30/2016	28	0	N/A	1	N/A
3/31/2016	30	0	N/A	1	N/A
12/31/2015	30	1	N/A	1	N/A
9/30/2015	29	0	N/A	2	N/A
6/30/2015	28	0	N/A	2	N/A
3/31/2015	26	0	N/A	1	N/A
12/31/2014	25	0	N/A	1	N/A
9/30/2014	25	0	N/A	0	N/A
6/30/2014	25	0	N/A	0	N/A
3/31/2014	24	0	N/A	0	N/A
12/31/2013	23	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if EVROF's forecast earnings growth is above the savings rate (2.5%).

Winst versus markt: Insufficient data to determine if EVROF's earnings are forecast to grow faster than the Greek market

Hoge groeiwinsten: Insufficient data to determine if EVROF's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if EVROF's revenue is forecast to grow faster than the Greek market.

Hoge groei-inkomsten: Insufficient data to determine if EVROF's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if EVROF's Return on Equity is forecast to be high in 3 years time

Evrofarma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

New minor risk - Earnings quality

First half 2024 earnings released: EPS: €0.10 (vs €0.10 in 1H 2023)

Upcoming dividend of €0.05 per share

Evrofarma SA to Report First Half, 2024 Results on Sep 24, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Financial data availability

Evrofarma SA to Report Fiscal Year 2023 Results on Mar 29, 2024

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

New major risk - Share price stability

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Investor sentiment improves as stock rises 18%

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

New major risk - Revenue and earnings growth

Evrofarma SA to Report First Half, 2023 Results on Sep 21, 2023

Evrofarma SA, Annual General Meeting, Jul 27, 2023

First half 2022 earnings released: €0.002 loss per share (vs €0.048 profit in 1H 2021)

Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Evrofarma SA to Report First Half, 2022 Results on Sep 27, 2022

Evrofarma SA, Annual General Meeting, Jul 28, 2022

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

First half 2021 earnings released: EPS €0.048 (vs €0.025 in 1H 2020)

Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

Investor sentiment improved over the past week

New 90-day low: €0.79

Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

New 90-day high: €0.88

Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

New 90-day high: €0.82

New 90-day low: €0.72

First half earnings released

New 90-day low: €0.74

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven